Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) - Pipeline Review, H1 2016

Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) - Pipeline Review, H1 2016
Published Jun 28, 2016
72 pages — Published Jun 28, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) - Pipeline Review, H1 2016, provides in depth analysis on Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) targeted pipeline therapeutics.

The report provides comprehensive information on the Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227)
- The report reviews Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) targeted therapeutics and enlists all their major and minor projects
- The report assesses Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insi

  
Source:
Document ID
GMDHC0145TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents25
  List of Tables51
  List of Figures61
Introduction71
  Global Markets Direct Report Coverage71
Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) Overview81
Therapeutics Development93
  Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) Products under Development by Stage of Development91
  Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) Products under Development by Therapy Area101
  Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) Products under Development by Indication111
Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) Pipeline Products Glance122
  Late Stage Products121
  Early Stage Products131
Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) Products under Development by Companies142
Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) Products under Development by Universities/Institutes162
Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) Therapeutics Assessment186
  Assessment by Monotherapy/Combination Products181
  Assessment by Mechanism of Action191
  Assessment by Route of Administration202
  Assessment by Molecule Type222
Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) Companies Involved in Therapeutics Development247
  Akshaya Bio Inc.241
  Boehringer Ingelheim GmbH251
  Etubics Corporation261
  Merck KGaA271
  Minerva Biotechnologies Corporation281
  Transgene SA291
  Vaxil Bio Therapeutics Ltd.301
Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) Drug Profiles3128
  BI-1361849 Drug Profile312
  GO-2032c Drug Profile332
  ImMucin Drug Profile354
  Monoclonal Antibody to Inhibit MUC1 for Solid Tumors Drug Profile391
  tecemotide Drug Profile404
  TG-4010 Drug Profile444
  Vaccine 1 to Target MUC-1 Protein for Breast Cancer Drug Profile481
  Vaccine 2 to Target MUC-1 Protein for Breast Cancer Drug Profile491
  Vaccine 3 to Target MUC-1 Protein for Breast Cancer Drug Profile501
  Vaccine for Oncology Drug Profile511
  Vaccine for Oncology Drug Profile521
  Vaccine to Target MUC-1 and TLR-2 for Breast Cancer Drug Profile531
  Vaccine to Target MUC1 for Oncology Drug Profile541
  Vaccine to Target MUC1 for Oncology Drug Profile551
  Vaccine to Target MUC1 for Oncology Drug Profile561
  Vaccine to Target MUC1 for Oncology Drug Profile571
  Vaccine to Target MUC1 for Oncology Drug Profile581
Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) Dormant Projects591
Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) Discontinued Products601
Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) Featured News &Press Releases6110
  Mar 31, 2016: Vaxil Receives Canadian Notice of Patent Allowance for Its Lead Immunotherapy Platform, Including Its ImMucin Cancer Vaccine611
  Dec 23, 2015: Transgene Announces Publication in The Lancet Oncology of Phase 2b TIME Trial Results with TG4010 Immunotherapy in Non-Small Cell Lung Cancer611
  Sep 08, 2015: Transgene Announces Final Overall Survival Data from Phase 2b TIME Trial with TG4010 Immunotherapy in Non-Small Cell Lung Cancer621
  Aug 19, 2015: Transgene Announces Oral Presentation on TG4010 Cancer Immunotherapy at World Conference on Lung Cancer631
  Jun 22, 2015: Vaxil's Lead Product ImMucin has Been Granted an Orphan Drug Designation by the FDA for the Treatment of Multiple Myeloma631
  Jun 01, 2015: Transgene Announces Positive New Results Presented at ASCO from Phase 2b TIME Trial with TG4010 Immunotherapy in Non-Small Cell Lung Cancer641
  Apr 21, 2015: Transgene Presents New Pre-Clinical Data at AACR on the Combination of TG4010 with Immune Checkpoint Inhibitors651
  Mar 16, 2015: VAXIL Receives EU Orphan Drug Designation for ImMucin for the Treatment of Multiple Myeloma651
  Jan 21, 2015: NCCS Conducts World s First-In-Human Clinical Trial Of A Novel Cancer Vaccine Targeting Top Cancers In Singapore661
  Dec 15, 2014: Vaxil publishes the results of its Phase I/II study using ImMucin in Myeloma Patients in the "British Journal of Hematology"671
  Nov 09, 2014: Vaxil has published a review article describing key advantages for its VaxHit technology671
  Sep 29, 2014: Transgene Presents Additional Positive Clinical Data from Phase 2b Part of TIME Trial with TG4010 at ESMO681
  Sep 12, 2014: Merck Discontinues Clinical Development Program of Tecemotide as a Monotherapy in Stage III Non - Small Cell Lung Cancer691
  Aug 18, 2014: Merck Announces Clinical Failure Of Tecemotide Cancer Vaccine691
  Aug 12, 2014: MicroVAX Cancer Vaccine First in Human Clinical Trial in Singapore701
Appendix712
  Methodology711
  Coverage711
  Secondary Research711
  Primary Research711
  Expert Panel Validation711
  Contact Us711
  Disclaimer721

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) - Pipeline Review, H1 2016" Jun 28, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Mucin-1-MUC-1-or-Breast-Carcinoma-Associated-Antigen-DF3-or-Carcinoma-Associated-Mucin-or-CD227-Pipeline-Review-H1-2016-2088-16047>
  
APA:
Global Markets Direct - Market Research. (2016). Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) - Pipeline Review, H1 2016 Jun 28, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Mucin-1-MUC-1-or-Breast-Carcinoma-Associated-Antigen-DF3-or-Carcinoma-Associated-Mucin-or-CD227-Pipeline-Review-H1-2016-2088-16047>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.